Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

The Penn Center for Personalized Diagnostics performs large-scale, parallel DNA sequencing and chromosomal analysis to screen hematologic and solid tumors for a wide spectrum of mutations. This video offers a detailed rendering of the workflow for the genomic sequencing process from its initiation at DNA extraction, through the generation and sequencing of an amplicon library via one of two next-generation sequencing (NGS) panels (one for each tumor category) and finally, data analysis through the in-house bioinformatics pipeline wherein the variants are reviewed and interpreted for pathogenicity.